Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Hugel Inc. has forged a distribution partnership with Sihuan Pharmaceutical for its Letybo botulinum toxin product after becoming the first South Korean brand approved to enter the Chinese market.
China’s National Medical Products Administration recently approved Hugel's Letybo for local sales.
Sihuan Pharmaceutical, which has a network of over 10,000 hospitals and medical institutions, will expedite Hugel's entry into the Chinese botox market.
Hugel hopes to take a 30 percent share within three years of the product launch and is aspiring to become the top botox brand in the country.
The South Korean biopharmaceutical firm is also eyeing to enter the European market in 2021 and the US market in 2022.
The market is estimated to be worth 1.75 trillion won by 2025.
Hugel is now one of the four companies, including US’ Allergan, French company Ipsen’s Dysport, and Chinese company Lanzhou Institute of Biological Products’ Hengli, authorized to trade in the Chinese botox market.
Due to its continued economic growth and increasing attention for beauty and appearance, China is expected to have increased demand for BTX products.
